CD8A and breast cancer: Anti-LGR5-ADC therapy is also a logical combination with the newly approved Tecentriq-Abraxane combo, which enhances CD8+ T cell killing through inhibiting PD-L1 [27], to heighten complete tumor regression along with durable responses in the deadly high-grade ER− LGR5high BC.